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Abstract: The Medication-Related Osteonecrosis of Jaws (MRONJ) diagnosis process and its
prevention play a role of great and rising importance, not only on the Quality of Life (QoL) of
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patients, but also on the decision-making process by the majority of dentists and oral surgeons
involved in MRONJ prevention (primary and secondary). The present paper reports the update of
the conclusions from the Consensus Conference—held at the Symposium of the Italian Society of Oral
Pathology and Medicine (SIPMO) (20 October 2018, Ancona, Italy)—after the newest recommendations
(2020) on MRONJ were published by two scientific societies (Italian Societies of Maxillofacial Surgery
and Oral Pathology and Medicine, SICMF and SIPMO), written on the inputs of the experts of
the Italian Allied Committee on ONJ (IAC-ONJ). The conference focused on the topic of MRONJ,
and in particular on the common practices at risk of inappropriateness in MRONJ diagnosis and
therapy, as well as on MRONJ prevention and the dental management of patients at risk of MRONJ.
It is a matter of cancer and osteometabolic patients that are at risk since being exposed to several
drugs with antiresorptive (i.e., bisphosphonates and denosumab) or, more recently, antiangiogenic
activities. At the same time, the Conference traced for dentists and oral surgeons some easy applicable
indications and procedures to reduce MRONJ onset risk and to diagnose it early. Continuous updating
on these issues, so important for the patient community, is recommended.
Keywords: MRONJ; prevention models; dentistry; oral surgery; bisphosphonates; denosumab;
antiresorptive drugs; antiangiogenic agents; cancer; osteoporosis
1. Introduction
Medication-Related Osteonecrosis of Jaws (MRONJ) and its prevention play a role of great and
rising importance, not only on the Quality of Life (QoL) of patients, but also on the decision-making
process of the majority of dentists and oral surgeons, involved every day in MRONJ prevention
(primary and secondary). The present report illustrates the update of conclusions adopted from the
Consensus Conference held at the Symposium of the Italian Society of Oral Pathology and Medicine
(SIPMO) on 20 October 2018, in Ancona (IT), when opinions were discussed and synthesized by
24 Italian experts. The Conference was the first national consensus to address the MRONJ disease and
specific interventions [1–3], it shared the definition of MRONJ as an “adverse drug reaction described as
the progressive destruction and death of bone that affects the mandible and maxilla of patients exposed
to the treatment with medications known to increase the risk of disease, in the absence of a previous
radiation treatment” [4], to be diagnosed and scored by clinics and radiographs [5], independently
from the presence of exposed necrotic bone or bone probing via sinus/fistula tracts for more than
8 weeks [6–11].
The present report was considered by the experts as convenient and worthwhile in the light of
the new findings [10,12,13] and the publication, in June 2020, of the new recommendations (2020) on
MRONJ by SICMF/SIPMO [14], written on the inputs of the experts of the Italian Consensus group on
ONJ (IAC-ONJ). Some good practices were confirmed, while others were partially or fully updated
(e.g., a drug holiday in osteometabolic patients, see Section 2.5); additionally, figures and tables have
been added to some issues to emphasize some of the good practices.
The updated Consensus Conference focused on the common practices still at risk of
inappropriateness in MRONJ diagnosis and prevention, and on the dental management of patients
exposed to ONJ. It is matter for the cancer (principally) and osteometabolic patients, since they are
exposed to an increasing number of drugs with antiresorptive (i.e., bisphosphonates and denosumab)
or antiangiogenic activities (e.g., bevacizumab; aflibercept; inhibitors of Tyrosine Kinases, TKIs;
and mTOR inhibitors) [6,8,11,15–18]. At the same time, the authors updated the easy applicable
indications and procedures for dentists and oral surgeons, in order to reduce MRONJ onset risk and to
diagnose it early [14,19].
The experts focused on the topic of MRONJ using the following 6 main subcategories (issues):
(1) clinical diagnosis; (2) radiologic diagnosis; (3) primary prevention (before and during drug
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intake); (4) dental management; (5) drug holiday (temporary suspension vs. therapeutic suspension);
and (6) therapy.
The IAC-ONJ planned that a recommended practice equivalent will be advised for any inappropriate
practice, within these 6 issues.
2. The Six Issues
2.1. Clinical Diagnosis of MRONJ: Practices at Risk of Inappropriateness and Good Practices
Assume that the Italian Consensus adopted the previously described definition of MRONJ [4,5],
as being diagnosed and scored by clinics and appropriate imaging; besides the presence of only exposed
necrotic bone or bone probing via sinus/fistula tracts for more than 8 weeks [7–11,20,21], the following
practices for diagnosis were considered at risk of inappropriateness.
2.1.1. Questionable Practices
(#1) Restricting the anamnestic interview only to the assumption of bisphosphonates for
diagnosing MRONJ.
(#2) Carrying out routine bone biopsies when suspecting an MRONJ.
(#3) Considering the presence of exposed necrotic bone, in the oral cavity, as an essential (conditio
sine qua non) sign to diagnose MRONJ.
(#4) Judging the presence of pain as an essential symptom for diagnosing MRONJ.
(#5) Believing that all MRONJ are preceded by dental invasive procedures.
2.1.2. Good Practices
(#1) Evaluate not only the intake of bisphosphonate drugs (current or past), but also further
pharmacological therapies (e.g., other antiresorptive agents, or drugs with anti-angiogenic activity)
and perform a thorough physical examination and medical history, together with targeted radiologic
examinations (see Section 2.2) (confirmed).
(#2) Perform jaw bone biopsies only if there is a suspicion of metastases in cancer
patients (confirmed).
(#3) Take into the account not only the presence of exposed necrotic bone but considering also
other clinical signs and first/second-level imaging (confirmed).
(#4) Consider that the symptom “pain” may not always be present in MRONJ cases, especially in
the early stages (confirmed).
(#5) Consider that some cases of MRONJ can arise from the presence of dental-periodontal diseases
or spontaneously, without any relation to invasive dental procedures (confirmed).
2.2. Radiologic Diagnosis of MRONJ: Practices at Risk of Inappropriateness and Good Practices
Radiologic imaging is assumed to be a fundamental tool for diagnostic completion, defining the
extent of the disease at the skeletal level, staging and the correct therapeutic planning. Even if it is well
known that no specific radiological signs of disease can be defined until now, an increasing volume of
evidence recognizes some radiological characteristics that, although non-specific, are associated with
MRONJ [6,9,13,22–25]. The use of radiological procedures must be aimed at the diagnostic/therapeutic
advantage, in order to reduce the high social and biological costs deriving from radiation exposure [21].
MRONJ is definitely a bone disease that frequently affects the soft tissues, so it requires targeted
imaging methods for diagnostic definition (first- and second-level exams) [13,26]. Only in cases of
doubtful diagnosis may it be useful to resort to additional investigations, such as Magnetic Resonance
(MR) and Nuclear Medicine tools (third-level exams), unless they are to be performed to monitor
neoplastic disease, and not specifically prescribed for an MRONJ diagnosis.
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2.2.1. Questionable Practices
(#1) Starting therapies at risk of ONJ without a radiologic assessment of dental arches, remarkably
in cancer patients.
(#2) Omitting the radiologic assessment for those patients at risk of MRONJ in the presence of
dental/endo-periodontal diseases.
(#3) Prescribing to everybody exposed to therapies at risk of ONJ all imaging techniques to rule
out MRONJ.
(#4) Requiring radiologic exams without a specific diagnostic hypothesis.
(#5) Prescribing radiological exams for MRONJ only after onset of jawbone exposure.
(#6) Diagnosing MRONJ only on the basis of the clinical signs, without radiologic assessment.
(#7) Prescribing high-resolution imaging for soft tissue (with contrast medium) for diagnosis
of MRONJ.
(#8) Planning MRONJ treatment without second-level imaging exams for assessing jawbone
disease extension and severity.
(#9) Monitoring the extension of the MRONJ process only by investigations of first-level exams
(e.g., panoramic X-ray).
2.2.2. Good Practices
(#1) Evaluate clinically and radiologically any local risk factors for MRONJ (i.e., dental/endo-
periodontal diseases) for preventive dental screening in patients, remarkably cancer ones, who are
candidates for therapies at higher risk of MRONJ; sometimes, MRONJ could manifest like a
dental/endo-periodontal disease, or a worsening of a pre-existent disease (updated) [12].
(#2) Perform radiological exams in all cases of dental/endo-periodontal diseases in patients at risk
of MRONJ (confirmed).
(#3) Reserve the indication for the execution of radiological exams of the second level
(e.g., Computed Tomography, CT) to patients at MRONJ risk only in the presence of ascertained clinical
or radiologic signs compatible with MRONJ (confirmed) [6,9,22].
(#4) Specify always the diagnostic hypothesis when prescribing radiological exams of any level
(X-ray panoramic, CT) in patients at MRONJ risk (confirmed).
(#5) Do not delay in prescribing radiologic exams to investigate any clinical signs of possible
MRONJ, independent of the presence of bone exposure or fistulas (updated).
(#6) Integrate always the clinical check-up with the appropriate imaging exams for the diagnosis
of MRONJ (confirmed).
(#7) Prescribe radiologic exams for bone diseases without contrast medium for diagnosis of
MRONJ (confirmed).
(#8) Set up the MRONJ treatment after defining its extension and severity also by targeted
imaging (confirmed).
(#9) Use targeted imaging (i.e., CT every 6 months) to monitor MRONJ during follow-up after
conservative and/or surgical treatment (updated).
2.3. Prevention of MRONJ: Practices at Risk of Inappropriateness and Good Practices
Assuming that recently it has been confirmed that MRONJ prevention means applying the correct
protocols of (1) primary prevention for both pre-treatment and in-treatment patients, and (2) secondary
prevention (i.e., early diagnosis of MRONJ) [5], the Consensus Conference believes that these principles
should be followed by key figures such as physicians, drug prescribers, dentists and oral hygienists.
Primary prevention for MRONJ mainly means elimination/reduction of the oral and dental risk
factors [5,11,15,27–29]; it is targeted at restoring and/or maintaining good oral health and reducing
the risk of onset of pathological conditions or any other negative event. This approach has the
greatest impact when aimed to constantly take care of oral health in patient at risk of MRONJ. Initially,
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about sixteen years ago, MRONJ (at that time labelled ONJ or BRONJ) was thought to be associated with
dental extractions (or dentoalveolar surgery) in patients already being treated with bisphosphonates.
More recently, infections at the dental-periodontal and peri-implant sites has been underlined as being
one of the main local risk factors of developing MRONJ [12]. Intriguingly, these infections are often the
main reason for surgical procedures of dental extraction or implant removal during or after therapy.
It is advisable to consult the newest recommendations (2020) on MRONJ published by the two Italian
scientific societies SICMF/SIPMO for a complete list of systemic and local risk factors [14] (Table 1).
Table 1. Drug-related, systemic and local risk factors of Medication-Related Osteonecrosis of
Jaws (MRONJ).
Risk Factor
Drug-Related Systemic Local
Product
(Antiresorptive/antiangiogenic drug)
Route of administration (po, sc, iv, im)
Cumulative dosage
Duration of treatments
Supportive care (e.g., chemotherapy,
steroids, thalidomide)
Underlying disease (solid tumors,
multiple myeloma, osteoporosis)
Comorbidity (e.g., diabetes,
rheumatoid arthritis,
hypocalcemia,
hyperparathyroidism)
Lifestyle (e.g., smoking)
Dental/periodontal infection
Peri-implantitis
Oral surgeries (e.g., dental extractions)
Unfitting removable dentures
Anatomical conditions (e.g., torus,
exostosis, pronounced mylohyoid ridge)
A new emerging and huge aspect is that primary prevention should be performed not only prior
to taking the MRONJ-related drugs but also during and after the treatment with antiresorptive agents
(AR), in order to eliminate any infective outbreaks of MRONJ. It is the responsibility of the dentist
to accurately assess the risk factors leading to the development of MRONJ and suggest a strategy to
remove these factors or minimize the risk. The dentist must also stress the importance of maintaining
effective dental hygiene (together with dental hygienist), including regular check-ups, for the patient.
Both are necessary to maintain oral health, reducing the outbreak of MRONJ and/or detecting possible
signs of the early symptoms of this disease.
Secondary prevention or early diagnosis is the second pillar in the strategy against MRONJ,
since we know that MRONJ diagnosed at an early stage is more likely to be treated successfully.
With respect to the diagnostic work-up, the main problem is the possible under-diagnosing of MRONJ
cases without bone exposure (or fistula). A recent multicenter study [22,30] has demonstrated that the
use of the traditional AAOMS [31,32] and ASBMR case definitions [33] may result in up to a quarter of
undiagnosed BRONJ cases [34–36]. Thus, in order to avoid any underestimation of MRONJ, care should
be taken with respect to the definition adopted by the Italian societies and to the use of the imaging
studies in both cancer and osteometabolic patients, who are already receiving MRONJ-associated
therapies, in combination or alone [8,28].
2.3.1. Questionable Practices
(#1) Keeping teeth with endodontic and/or periodontal diseases at uncertain prognosis only to
avoid extractive and invasive procedures, in patients at risk of MRONJ.
(#2) Extracting teeth in partial or total inclusion for pure preventive purposes in patients that are
candidates for treatment with drugs at risk of inducing MRONJ.
(#3) Scheduling in cancer patients the first dental check-up only after diagnosis of bone metastases.
(#4) Omitting in osteometabolic patients dental check-ups for oral health status assessment and
relative preventive dentistry actions.
(#5) Omitting periodic dental check-ups for edentulous patients or wearing removable prostheses,
if they are at risk of MRONJ.
(#6) Underestimating the usefulness of the imaging performed to evaluate cancer disease extension
(i.e., bone scintigraphy; CT-PET) with respect to MRONJ early diagnosis (and follow-up).
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2.3.2. Good Practices
(#1) Extract teeth with endodontic and/or periodontal diseases, in patients at risk of MRONJ,
when a conservative approach is not possible and a good tooth prognosis is not guaranteed (confirmed).
(#2) Maintain teeth in partial or total inclusion, if no sign and/or symptom is present
(e.g., dysodontiasis, pericoronitis, decay, periodontal disease, caries and/or root resorption of the
second molar, and mechanical trauma on the surrounding mucous membranes) (confirmed).
(#3) Schedule in cancer patients the first dental check-up as soon as possible, preferably during
the tumor staging process (confirmed).
(#4) Consider in osteometabolic patients (generally at lower risk of MRONJ than cancer patients)
a potential gradient in MRONJ risk (Figure 1) (updated) [19].
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Figure 1. MRONJ risk profile of patients ith etabolic bone fragility receiving AR medications [19].
* It includes also CTIBL patients (hormone deprivation therapy induced bone loss in breast and prostate
cancer patients without bone metastases).
(a) Administration and duration of treatment with MRONJ-related drugs [5,6,37,38]; consider in
this category cancer patients receiving antiresorptive agents for the prevention of osteoporosis induced
by hormone therapy (Cancer Treatment Induced Bone Loss, CTIBL), with a risk of MRONJ being
considerably lower than that of cancer patients receiving AR drugs for bone metastases or myeloma;
(b) Eventual presence of comorbidities and further medical therapies indirectly associated; assess,
during the prescription of the MRONJ-associated rugs, the oral healt status even by a questionnaire
(bypassing the preliminary dental check-up) (Figure 2) [39]; schedule semi-annual dent l visits (the first
one withi 6 months from the first assumption of antiresor tive drugs).
(#5) Schedul p eve tive de tal check-ups even in patients at risk MRONJ even if edentulous or
wearing removable dentures, in order to intercept and correct any injury on the oral mucosa (confirmed).
(#6) Research any sign of jawbone alterations in cancer patients, revising the pictures of the
imaging investigations (e.g., bone scintigraphy, CT-PET) already performed to stage the cancer disease,
in order to potentially detect eventual early signs of MRONJ, before prescribing further specific
imaging (updated).
2.4. Dental Management: Practices at Risk of Inappropriateness and Good Practices
Assume that the Consensus Conference has now adopted the new protocols for dental management
in patients at risk of MRONJ, published in the recommendations on MRONJ by the two scientific
societies SICMF/SIPMO [14], in which it re-evaluated its opinion on the following hot points:
(a) implants in cancer and osteometabolic patients; (b) antibiotic prophylaxis; and (c) healing for first
vs. second intention.
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Figure 2. Questionnaire for ONJ-related drug prescribers.
2.4.1. Questionable Practices
(#1) Building an implant rehabilitation in cancer patients who have to take or are taking
MRONJ-associated drugs due to advanced cancer disease.
(#2) Considering as contraindicated, in an absolute s nse, im lant rehabilitation in osteometabolic
patients taking MRONJ-associated drugs (including cancer patients treated with antiresorptive agents
for CTIBL).
Int. J. Environ. Res. Public Health 2020, 17, 5998 8 of 15
(#3) Prescribing antibiotic prophylaxis before non-invasive dental therapies.
(#4) Performing extractive procedures without removing, even if necessary, the alveolar bone,
and plan the healing as a second intention (especially with cortisone administration).
2.4.2. Good Practices
(#1) Avoid in cancer patients implant rehabilitation and plan non-surgical rehabilitation (confirmed).
(#2) Plan implant rehabilitation in osteometabolic patients taking into account the cumulative
dose of the drug already taken, the periodontal status, lifestyle (e.g., smoking), comorbidities and
other drugs. Share with the patient a hypothetical medium to long-term MRONJ risk due to
“implant presence-triggers” (such as peri-implantitis and micro-cracks), beside the lower probable
short-term risk due to “implant surgery-triggers” [29,40–43]. Plan informed consent and semi-annual
follow-ups (updated).
(#3) Recommend always, in patients at MRONJ risk, antibiotic prophylaxis when surgical
procedures involving the dento-alveolar process or maxillary bones are planned (e.g., extractions,
periodontal/endodontic surgery, implants and pre-implant surgery) (confirmed).
(#4) Practice extractive or surgical procedures planning the healing as the first intention with the
clot maintenance (confirmed).
2.5. Drug Holiday or Temporary Suspension for Patients at Risk of MRONJ: Practices at Risk of
Inappropriateness and Good Practices
Assuming that a drug holiday is a controversial issue, involving both drug prescribers (oncologists,
hematologists, bone health specialists and general practitioners) and oral and dental specialists, it is
important to clarify that “Drug holiday” can have at least two meanings in the medical literature when
referred to MRONJ. It can mainly mean (1) the temporary and preventative suspension of drug therapy
(i.e., bisphosphonates, denosumab and sometimes antiangiogenic drugs) in a patient at risk of MRONJ,
before the necessary dental procedures (tooth extraction or jawbone surgery); or (2) the suspension
of drug therapy (i.e., bisphosphonates, denosumab) due to a diagnosis of MRONJ, hypothetically
finalized to stop or to slow the osteonecrosis process (a practice with scarce literature as support).
This document will afford only the first meaning of a “drug holiday”.
It is well known that suspension of drug therapy can create different cost–benefit balances,
according also to the type of molecule in those two patient populations.
(a) In cancer patients with advanced disease (e.g., bone metastases or myeloma), suspension of
antiresorptive drugs has to be decided on the basis of a difficult balance between a possible positive
drug effect (reduction in the risk of Skeletal Related Events, SREs: bone fracture; need for radiotherapy;
need for bone surgery; and spinal cord compression) and a potentially higher risk of a side effect
anyway present (i.e., higher risk of MRONJ namely triggered by alveolar surgery). Clearly that balance
could individually change on the basis of the moment along the patient cancer history and along
the drug administration history: hypothetically, in the first months of drug administration for bone
metastases or myeloma, the suspension is potentially more harmful for the (lack of reduction of) risk
of SRE but less dangerous for the risk of triggering MRONJ; vice versa after two years of antiresorptive
administration, for example, the suspension appears less dangerous for the risk of SRE (anyway
present) whereas the risk of MRONJ (being higher with longer time and higher cumulative drug dose)
might receive maximum benefit from the suspension.
Furthermore, the balance might change on the basis of the different characteristics of the
antiresorptive drugs:
- BPs have a long half-life and are able to accumulate in the bone tissue, potentially influencing the
post-extractive bone tissue repair. Furthermore, for some largely used BPs (above all zoledronic
acid), a possible antiangiogenic effect was described in the literature, potentially reducing the
soft tissue repair process. Consequently, a precautionary and temporary suspension of the drug
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administration has been claimed by most of authors as potentially useful, even if no definitive
data have been published;
- Denosumab (Xgeva®), a monoclonal human anti-RANKL inhibitor, is a drug with a short half-life
and does not accumulate in the bone. A possible rebound effect on the bone turnover has been
described after drug withdrawal, so that some authors advised against a (long) suspension.
(b) Osteometabolic patients, cancer patients treated with antiresorptive agents for CTIBL or
people affected by other non-malignant diseases (e.g., Paget disease), receive antiresorptive drugs
at lower doses and less frequently (e.g., oral bisphosphonates; yearly 5 mg i.v. zoledronic acid;
and bi-yearly 60 mg s.c. denosumab). The fracture risk can be determined objectively and correctly by
applying the DeFRA79 algorithm validated by AIFA, the Italian version of the FRAX algorithm [44].
On the basis of the two different antiresorptive agents, they are classified as follows:
- BPs (e.g., alendronate, ibandronate) are synthetic analogues of pyrophosphates, which firmly
bind to the hydroxyapatite and reduce bone metabolism/remodeling [6]. The half-life of BPs in
circulation is short (ranging from 30 min to 2 h); however, once they have been incorporated into
bone tissue, they can persist more than 10 years, depending on the skeletal turnover time [11,45].
Usually, BPs (i.e., alendronate) is administered orally (e.g., 150 mg/every 4 week); in a few patients
BPs are administered intramuscularly (e.g., neridronate 2 mg/kg every 3 months) or intravenously
(e.g., zoledronate 5 mg/every 12 months) [6,14,45].
- Denosumab (Prolia®), a monoclonal human IgG2 antibody that highly binds the receptor activator
of nuclear factor-kB ligand (RANK-L), blocks the osteoclast maturation, function and survival.
Its half-life is 25–32 days and it does not amass in the bone with a peculiar regimen (1 dose s.c. of
60 mg every six months) [46–48]. The suspension of denosumab determines within the following
3–6 months the rebound of the fracture risk, especially in patients at high risk of fracture [47,49,50].
Of note, when a patient is treated with denosumab, after a previous BP administration, he/she must
be classified with the ONJ risk profile for the BP user.
2.5.1. Questionable Practices
(#1) Performing dental extraction or oral surgery in patients with active cancer and myeloma bone
disease and in therapy with i.v. high-dose bisphosphonates or denosumab (Xgeva®) without agreeing
any temporary suspension with the prescriber (oncologist/hematologist).
(#2) Suspending indiscriminately therapy with antiresorptive drugs (i.e., bisphosphonates,
denosumab) prescribed for osteoporosis (or its prevention), in case of necessity of extraction or
programmed oral surgery, without agreeing with the prescribing physician.
2.5.2. Good Practices
(#1) Plan, in cancer patients, combined assessment by the prescriber (i.e., high risk versus low
risk of fracture and other SREs) and by the dentist (i.e., high risk versus low risk of post-extraction
complications) to determine whether or not there is the need for a precautionary suspension of
i.v. high-dose bisphosphonate or denosumab (Xgeva®) before and after the dental procedure.
This combined assessment is mandatory in the absence of univocal data on the efficacy of the suspension
of bisphosphonates or denosumab to reduce the risk of “post-extraction” MRONJ, and in consideration
of conflicting data about the possible anti-angiogenic effect of zoledronic acid (Table 2) [51–54].
A suspension frequently applied consists of a period of 3 weeks, at least, from the last assumption
before any elective invasive oral or dental procedures, and for the necessary waiting time until mucosal
healing occurred before re-assumption (at least 4–6 weeks) (updated) [48,55,56].
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Table 2. Drug suspensions proposed for cancer and osteometabolic patients [14,19].
Drug Suspensions in Cancer Patients
Active Pharmaceutical Ingredient Last Administrations beforeSurgical Procedure Resume Treatment
Bisphosphonates At least 1 week before
At least 4–6 weeks after
surgical procedures
Denosumab (Xgeva®) At least 3 weeks before
Bevacizumab At least 5–8 weeks before
Sunitinib At least 1 week before
Drug Suspensions in Osteometabolic Patients
Active Pharmaceutical Ingredient Last Administrations beforeSurgical Procedure Resume Treatment
Bisphosphonates * At least 1 week before At least 4–6 weeks aftersurgical procedures
Denosumab (Prolia®) No suspension **
* Only in patients exposed to BPs for more than 3 years or in patients exposed to BPs for less than 3 years but in the
presence of other systemic or local risk factors (e.g., concomitant use of corticosteroids, diabetes, and rheumatoid
arthritis). ** It is still possible to maximize the pharmacokinetic of Prolia® and identify a time interval in those
postponable and non-critical dental/periodontal conditions requiring invasive treatment, and can ideally take place
without restrictions. This “delayed dosing window” lasts about 2 months, starts ideally 5 months after the last dose
of Prolia® and ends at the beginning of the 7th month.
(#2) Plan, in osteometabolic patients, a balanced and combined assessment by the prescriber
(i.e., high risk versus low risk of fracture) and by the dentist (i.e., high risk versus low risk of
post-extraction complications) to assess whether or not you need precautionary suspension of BPs or
postponing the denosumab (Prolia®) (updated). There are two different conditions (Table 2).
(a) Patient under BPs, a drug suspension may be already considered useful one week before
surgical procedures. BP administration can resume once the biological process of healing of the oral
tissues is completed (at least 4–6 weeks after surgery) [5,14];
(b) Patient under denosumab (Prolia®); it is still possible to take advantage of the pharmacokinetic
of Prolia® in order to define a time interval in those postponable and non-critical dental/periodontal
conditions requiring invasive treatment and can theoretically take place without restrictions.
This “delayed dosing window” lasts about 2 months, starts ideally 5 months after the last dose
of Prolia® and ends at the beginning of the 7th month. If the surgical dental procedure is assessed
as urgent and not procrastinable, it is recommended to apply the suspension scheme of denosumab
previously described for cancer patients [14,19].
2.6. MRONJ Therapy: Practices at Risk of Inappropriateness and Good Practices
Assume that the Consensus Conference embraced the principles and good practices promoted by
the new recommendations by SIPMO/SICMF (June 2020) with respect to therapeutic strategies [6,14];
it focuses, here, on the following hot topics: perioperative antibiotic regimen; bone biopsy in patients
suffering from clinical–radiological evidence of MRONJ; role of preoperative imaging; anticipated
surgery versus planned exfoliation (self-sequestration); the shaving and smoothing of bone surfaces
during surgical therapy; surgery-related quality of life issues for MRONJ patients; impact of the
type of medication on the treatment decision-making of patients with BP-related and non-BP related
(anti-RankL and/or targeted therapies) MRONJ; surgery for asymptomatic MRONJ; and the role of
bone turnover markers for surgery.
2.6.1. Questionable Practices
(#1) Forgetting the adoption of an adequate perioperative antibiotic regimen in case of surgical
treatment of MRONJ.
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(#2) Performing a diagnostic bone biopsy, unless bone metastases are suspected.
(#3) Applying of first-level imaging (e.g., dental X-ray and panoramic radiograph) only to plan
surgical treatment.
(#4) Awaiting the exfoliation (self-sequestration) of necrotic exposed bone via the use of
non-surgical therapies, since this process is unpredictable over time.
(#5) Neglecting shaving and smoothing of the bone surfaces as a mainstay of any surgical procedure.
(#6) Banishing the surgical option for MRONJ cancer patients based on general statements of
residual life expectancy.
(#7) Merging BP-related and non-BP-related (anti-RankL and/or targeted therapies) MRONJ
patients as a whole when considering temporary interruption of medications for surgical treatment.
(#8) Adopting surgical treatment of MRONJ in symptomatic cases only.
(#9) Relaying on systemic bone turnover markers to predict the success of surgical therapies in
MRONJ patients.
2.6.2. Good Practices
(#1) Prescribe a broad-spectrum antibiotic regimen as an integral part of surgical treatment:
high-dose amoxicillin/clavulanic acid (1000 mg TID), plus high-dose Metronidazole (500 mg TID),
from the day before surgery and up to the 10th post-operative day. Alternatives should be used in case
of reported allergy to penicillin (confirmed).
(#2) Perform a diagnostic bone biopsy in case of clinical and radiological suspicion of bone
metastases to the jaw or myeloma area, in order to distinguish them from site of MRONJ disease,
when clinically needed (confirmed).
(#3) Use second-level imaging tools, mainly computed tomography (CT), to appropriately plan
the extent of jawbone disease before surgery (confirmed).
(#4) Anticipate surgical treatment, whenever indicated, to reduce the surgical burden for MRONJ
patients and increase the likelihood of long-term healing (confirmed).
(#5) Always perform the shaving and smoothing of bone surfaces as a mainstay of any surgical
procedure to prevent further bone exposure (confirmed).
(#6) Plan the surgical treatment of MRONJ on an individual basis, weighing the impact and the
potential benefit of surgery on the general health status of patients (confirmed).
(#7) Discuss and plan the temporary interruption of any given medication in agreement with
the prescriber and based on its pharmacological properties, before initiating every MRONJ surgical
treatment (confirmed).
(#8) Adopt the early surgical treatment also in MRONJ asymptomatic patients (confirmed).
(#9) Do not rely on systemic bone turnover markers to establish individual treatment algorithms
for MRONJ, but carefully examine all potential factors that are likely to influence the long-term success
of therapies, including the underlying disease (cancer or non-cancer) and the type of medication
used (confirmed).
3. Conclusions
MRONJ is a potentially severe complication of antiresorptive and/or antiangiogenic treatment in
patients with skeletal events due to various cancers as well as osteometabolic diseases; MRONJ may
lead to a reduced quality of life due to jawbone infections, chronic pain, tooth loss and compromised
function. Although notable progress has been made, there remain a number of controversial aspects
on MRONJ, especially regarding pathogenesis, diagnosis and treatment.
The present paper updated conclusions from the Consensus Conference at the Symposium of
Italian Society of Oral Pathology and Medicine (SIPMO) (20 October 2018, Ancona, Italy), after the
newest recommendations on MRONJ were published in 2020 by two scientific societies (Italian Societies
of Maxillofacial Surgery and Oral Pathology and Medicine, SICMF and SIPMO), written on the inputs
of the experts of Italian Allied Committee on ONJ (IAC-ONJ). Some recommendations were confirmed.
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We defined six issues of MRONJ and submitted for every issue the current knowledge and the
appropriate best practices, in order to improve the management of patients.
We highlighted the importance to disclose the appropriate information about MRONJ, and the
statements and recommendations presented in this paper might represent a beneficial instrument both
at a national and international level to better understand and manage this singular and severe disease.
In the absence of clear knowledge on the etiology and given the continuous spread of the
application of new target therapies, it will be fundamental to continue the research, to report any cases
using new drugs and to clarify by evidence-based medicine all the controversial aspects of MRONJ.
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